Sponsored Links
MedicalResources
| Spectrum Pharmaceuticals Announces Completion Of Enrollment In One Apaziquone Phase 3 Pivotal Trial For Bladder Cancer Ahead Of Schedule |
 |
 |
 |
| Medical News - Cancer Oncology | |||
|
Spectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year... Read more: Cancer / Oncology News From Medical News Today
|